Navigation Links
Fate Therapeutics Granted Exclusive License By The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration

LA JOLLA, Calif., July 1 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed by Farhad Parhami, Ph.D., professor of medicine at University of California, Los Angeles, in collaboration with Michael Jung, Ph.D., professor of chemistry and biochemistry, and have been shown in vivo to exhibit osteo-regenerative activity. While many current medications aimed at addressing bone deficiencies work by preventing further decay, osteogenic agents stimulate positive bone growth and may offer an improved course of action in orthopedic medicine ranging from bone fractures to osteoporosis. The exclusive rights acquired today by Fate Therapeutics continue to bolster the Company's platform of Stem Cell Modulators (SCMs) - small molecules and biologics that seek to modulate adult stem cells within the body to guide cell fate for therapeutic purposes.

"Dr. Parhami and his research team have not only advanced the understanding of the biology around bone formation but also identified and created small molecules that may be used to induce the differentiation of adult stem cells in the body for osteo-regenerative medicine," said Paul Grayson, president and CEO of Fate Therapeutics. "The potential of these novel small molecules has been confirmed in several different in vivo proof of concept studies, and we look forward to their continued preclinical development for bone generation."

Adult stem cells are naturally-occurring cells found in almost all tissues or organs in the body and are primarily responsible for maintaining and repairing their native tissue. For example, mesenchymal stem cells are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes and adipocytes. Dr. Parhami's discovery of specific pathways and small molecules that can induce differentiation to mature, bone-forming osteoblasts offers a new mechanism of intervention, which may be applied to treat a number of bone injuries and conditions, including non-union fracture, spinal fusion or osteoporosis. By collaborating with the foremost researchers and clinicians in the field of adult stem cell biology, Fate Therapeutics is continuing to expand its leadership position in the discovery and development of SCMs for regenerative medicine.

"Having an industry partner is essential to a successful translational drug discovery project, and we are excited about our collaboration with Fate Therapeutics to realize the full potential of our discoveries," said Dr. Parhami. "Our work has uncovered novel strategies and mechanisms for lineage-specific differentiation to an osteoblast phenotype. The ability to activate specific populations of stem cells in the body to promote bone regeneration may have many orthopedic clinical applications."

Dr. Parhami continued, "For example, with traumatic bone injuries, such as non-union fractures where the break in the bone cannot be healed without medical intervention, patients must undergo complicated surgeries and long recovery times. In the case of degenerative bone diseases, such as osteoporosis, current therapies focus on blocking bone degeneration rather than inducing formation. Being able to promote bone growth with novel osteogenic small molecules represents the next-generation of therapeutic agents for orthopedic medicine."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit

SOURCE Fate Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hyperion Therapeutics Raises $60 Million Series C
2. Cornerstone Therapeutics Joins the Russell 3000(R) Index
3. Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
4. Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market
5. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
6. Prospect Therapeutics Inc.s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers
7. Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
8. Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations
9. Leaders from the Field of Pain Therapeutics to Discuss Latest Discoveries and Breakthroughs at Arrowhead's 3rd Annual Pain Therapeutics Summit
10. Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System
11. Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Trustify is ... in Washington, DC, hosted by Becky’s Fund, an organization dedicated to ending domestic violence. ... and control back to battered victims and survivors of domestic violence. Trustify is also ...
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday ... to NASDAQ to educate the personnel on spinal decompression therapy and offer his ... a nonsurgical procedure. The benefits come from creating negative intradiscal pressure which is ...
(Date:12/1/2015)... , ... December 01, 2015 , ... The Multiple System ... awareness and funds for Multiple System Atrophy (MSA) research, timed today to coincide with ... many things from patients including their ability to work and be productive, to do ...
(Date:12/1/2015)... ... December 01, 2015 , ... The North American Meat ... that meat and poultry play in a healthy, balanced diet. , includes ... visitors can check their “meat IQ,” a section offering straight talk on controversies, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... World ... the Multi Jar, a container patent that allows for easier packing and organizing of ... US is worth $90 billion," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  CytoSorbents Corporation (NASDAQ: ... commercializing its CytoSorb® blood purification technology to reduce ... world, today announced that Dr. Phillip Chan ... to participate in the LD Micro Main Event ... Conference, both of which will be held in ...
(Date:12/1/2015)... BOULDER, Colo. , Dec. 1, 2015 ... ARRY ) today announced that its Chief ... present at the Oppenheimer Annual Healthcare Conference ... to participate in the conference through a ... , --> ...
(Date:12/1/2015)... Dec. 1, 2015 Assurex Health, Inc. ... test giving healthcare providers an expanded range of ... patients suffering from depression, anxiety, bipolar disorder, posttraumatic ... conditions. i .   ... With the addition of two new drug classes, ...
Breaking Medicine Technology: